A C177537 GDC Value Terminology C156427 Cancer-Related Death A death attributed to the progression of a cancer-related pathologic condition. Cancer Related | cause_of_death C81239 cause_of_death A C177537 GDC Value Terminology C179646 Endosalpingiosis A rare condition characterized by the replacement of the epithelium of an organ which is not related to fallopian tube with ectopic fallopian tube-type ciliated epithelium. Endosalpingiosis | risk_factor C17103 risk_factor A C177537 GDC Value Terminology C179441 Injected Insulin Diabetes Therapy The use of injected forms of insulin to treat diabetes. Injected Insulin | diabetes_therapy C99532 diabetes_treatment_type A C177537 GDC Value Terminology C179442 N6-Methyladenine RNA Analysis An assay that quantitates the amount and identifies the location of N6-methyladenine modifications within an RNA sequence. m6A RNA Methylation | experimental_strategy || m6A RNA Methylation | library_strategy C177618 || C43622 library_strategy || experimental_strategy A C177537 GDC Value Terminology C179443 Macroscopically Positive Parametrial Margin The presence of macroscopically visible residual tumor in surgical margins in the parametrial region. Macroscopic Parametrium | hysterectomy_margins_involved C177594 hysterectomy_margins_involved A C177537 GDC Value Terminology C179445 Microscopically Positive Parametrial Margin The presence of microscopically visible residual tumor in surgical margins in the parametrial region. Microscopic Parametrium | hysterectomy_margins_involved C177594 hysterectomy_margins_involved A C177537 GDC Value Terminology C179446 mirVana RNA Isolation A proprietary, rapid procedure using a glass fiber filter (GFF)-based method to purify total RNA from a sample. The total RNA can then be reapplied to a second GFF to purify small RNAs (miRNAs, siRNAs, and/or snRNAs). mirVana (Allprep DNA) RNA | experimental_protocol_type C177560 experimental_protocol_type A C177537 GDC Value Terminology C179447 Non-Cohesive Pattern A microscopic finding where the cells in a sample are arranged, singly or in small clusters, demonstrate loose adhesion with one another and may not be distributed uniformly. Non-cohesive | morphologic_architectural_pattern C35886 morphologic_architectural_pattern A C177537 GDC Value Terminology C179448 Oral Hypoglycemic Diabetes Therapy The use of oral hypoglycemic agents to treat diabetes. Oral Hypoglycemic | diabetes_therapy C99532 diabetes_treatment_type A C177537 GDC Value Terminology C179449 Pre-extracted DNA Received by TSS Indicator An indication that a DNA sample received by the tissue sample coordination site (TSS) had been isolated by the site that initially collected the tissue samples from the subject. Pre-extracted DNA received by TSS | experimental_protocol_type C177560 experimental_protocol_type A C177537 GDC Value Terminology C179450 Primary Tumor Field The anatomic site(s) surrounding and including a primary tumor. Primary Tumor Field | treatment_anatomic_site C70729 treatment_anatomic_site A C177537 GDC Value Terminology C179451 Primary Tumor Site The anatomic location of a primary tumor. Primary tumor site | treatment_anatomic_site C70729 treatment_anatomic_site A C177537 GDC Value Terminology C179452 Estrogen/Progesterone Hormone Replacement Therapy A combination of estrogen and progesterone given to postmenopausal women or to women who have had their ovaries surgically removed. Progesterone and Estrogen | hormone_replacement_therapy_type C15599 hormone_replacement_therapy_type A C177537 GDC Value Terminology C179453 Progesterone Only Hormone Replacement Therapy Progesterone given to postmenopausal women or to women who have had their ovaries surgically removed. Progesterone only | hormone_replacement_therapy_type C15599 hormone_replacement_therapy_type A C177537 GDC Value Terminology C179455 Progestin Only Hormonal Contraception A hormonal contraceptive that utilizes progestin (synthetic progesterone) to prevent implantation and pregnancy. Progestin | hormonal_contraceptive_type C92808 hormonal_contraceptive_type A C177537 GDC Value Terminology C179456 Combination Estrogen/Progestin Hormonal Contraception A hormonal contraceptive that utilizes a combination of estrogen and progestin (synthetic progesterone) to prevent ovulation and pregnancy. Progestin and Estrogen | hormonal_contraceptive_type C92808 hormonal_contraceptive_type A C177537 GDC Value Terminology C179457 Regional Site Receiving Treatment The anatomic site that is located near the primary disease site and is targeted by a medical intervention. Regional Site | treatment_anatomic_site C70729 treatment_anatomic_site A C177537 GDC Value Terminology C179458 Single Cell ATAC-Seq A molecular genetic technique where DNA is isolated from single cell (sc) samples and amplified to create a genomic library. Then the library is subjected to ATAC-seq, which isolates and sequences regions rich in open chromatin. scATAC-Seq | library_strategy C177618 || C43622 library_strategy || experimental_strategy A C177537 GDC Value Terminology C179424 Abnormal Glucose Level Finding A finding that either fasting or postprandial blood glucose levels are above or below the normal thresholds. Abnormal Glucose Level | comorbidity || Abnormal Glucose Level | risk_factor C16457 || C17103 comorbidity || risk_factor A C177537 GDC Value Terminology C179426 Ancient DNA Isolation Any method that extracts and purifies DNA from ancient, historical, mummified or fossilized biological samples. aDNA Preparation Type | experimental_protocol_type C177560 experimental_protocol_type A C177537 GDC Value Terminology C179428 AllPrep FFPE DNA Isolation A method that extracts and purifies DNA from formalin-fixed paraffin-embedded samples using the proprietary AllPrep kit (Qiagen). Allprep FFPE DNA | experimental_protocol_type C177560 experimental_protocol_type A C177537 GDC Value Terminology C179430 AllPrep RNA Isolation A method to isolate total RNA from a biospecimen that uses the proprietary AllPrep RNeasy MinElute spin column (Qiagen). Allprep RNA Extraction | experimental_protocol_type C177560 experimental_protocol_type A C177537 GDC Value Terminology C179431 Chemical Lysis DNA Extraction Any method of DNA extraction that uses chemicals, rather than mechanical or enzymatic means, to disrupt the cells in the sample. Chemical Lysis DNA Extraction | experimental_protocol_type C177560 experimental_protocol_type A C177537 GDC Value Terminology C179432 Cohesive Pattern A microscopic finding that the cells in the sample are tightly adhered to one another and distributed uniformly. Cohesive | morphologic_architectural_pattern C35886 morphologic_architectural_pattern A C177537 GDC Value Terminology C179433 Distant Site Receiving Treatment The anatomic site that is located away from the primary disease site and is the target of a medical intervention. Distant Site | treatment_anatomic_site C70729 treatment_anatomic_site A C177537 GDC Value Terminology C179434 Estrogen Only Hormone Replacement Therapy The use of estrogen in postmenopausal women or to women who have had their ovaries surgically removed. Estrogen only | hormone_replacement_therapy_type C15599 hormone_replacement_therapy_type A C177537 GDC Value Terminology C179435 HiChIP A method that combines chromosome conformation capture, proximity ligation and chromatin immunoprecipitation to isolate DNA from a biospecimen, create a genomic library and analyze 3D chromatin organization. HiChIP | experimental_strategy || HiChIP | library_strategy C177618 || C43622 library_strategy || experimental_strategy A C177537 GDC Value Terminology C179436 FFPE MicroRNA Isolation A method that extracts RNA from formalin-fixed paraffin-embedded samples and then isolates the microRNA fraction. HighPure miRNA (Allprep DNA) FFPE RNA | experimental_protocol_type C177560 experimental_protocol_type A C177537 GDC Value Terminology C179438 Incomplete Terminal Codon Variant A change in the nucleotide sequence of at least one base of the final codon of a incompletely annotated transcript. Incomplete Terminal Codon Variant | molecular_consequence C97926 molecular_consequence A C177537 GDC Value Terminology C8106 Ovarian Dysgerminoma A malignant germ cell tumor arising from the ovary. Morphologically, it is identical to seminoma and consists of a monotonous population of germ cells with abundant pale cytoplasm and uniform nuclei. The stroma invariably contains chronic inflammatory cells, mostly T-lymphocytes. It responds to chemotherapy or radiotherapy and the prognosis relates to the tumor stage. 9060/3 | morphology || Dysgerminoma | primary_diagnosis C176985 || C177621 morphology || primary_diagnosis A C177537 GDC Value Terminology C7009 Central Nervous System Germinoma A malignant germ cell tumor arising from the central nervous system. It is composed of uniform cells resembling primitive germ cells. These cells have large, vesicular nuclei, prominent nucleoli and a clear, glycogen-rich cytoplasm. Additional features are lymphoid or lymphoplasmacytic infiltrates and, less frequently, scattered syncytiotrophoblastic giant cells. (Adapted from WHO) 9064/3 | morphology || Germinoma | primary_diagnosis C176985 || C177621 morphology || primary_diagnosis A C177537 GDC Value Terminology C166939 Onfekafusp Alfa An immunocytokine consisting of human pro-inflammatory cytokine tumor necrosis factor alpha (TNFalpha) fused to a human single-chain variable fragment (scFv) directed against the extra-domain B (ED-B) of fibronectin (L19), with potential immunopotentiating and antineoplastic activities. Upon adinistration, the L19 moiety of onfekafusp alfa binds to the ED-B domain of fibronectin on tumor cells in the tumor neovasculature. In turn, the TNFalpha moiety may locally induce an immune response against ED-B fibronectin-expressing tumor cells and may specifically decrease the proliferation of ED-B-expressing tumor cells. ED-B is predominantly expressed during angiogenesis and tumor growth. Fibromun | therapeutic_agents C1909 therapeutic_agents D C177537 GDC Value Terminology C8278 Cancer-Related Condition A disorder either associated with an increased risk for malignant transformation (e.g., intraepithelial neoplasia, leukoplakia, dysplastic nevus, myelodysplastic syndrome) or that develops as a result of the presence of an existing malignant neoplasm (e.g., paraneoplastic syndrome). Cancer Related | cause_of_death C81239 cause_of_death D C177537 GDC Value Terminology C94210 Fibromun An immunocytokine consisting of human pro-inflammatory cytokine tumor necrosis factor alpha (TNFalpha) fused to a human single-chain variable fragment (scFv) directed against the extra-domain B (ED-B) of fibronectin (L19), with potential immunopotentiating and antineoplastic activities. The L19 moiety of recombinant human fusion protein L19TNFalpha binds to the ED-B domain of fibronectin on tumor cells in the tumor neovasculature. In turn, the TNFalpha moiety may locally induce an immune response against ED-B fibronectin-expressing tumor cells and may specifically decrease the proliferation of ED-B-expressing tumor cells. ED-B is predominantly expressed during angiogenesis and tumor growth. Fibromun | therapeutic_agents C1909 therapeutic_agents D C177537 GDC Value Terminology C3753 Germinoma A malignant germ cell tumor arising in the central nervous system. It is characterized by the presence of primitive, large malignant germ cells and lymphocytes. 9064/3 | morphology || Germinoma | primary_diagnosis C176985 || C177621 morphology || primary_diagnosis D C177537 GDC Value Terminology C40121 Endosalpingiosis A benign pathologic process characterized by the transformation of the mesothelium into fallopian tube epithelium. It occurs in the peritoneum and may affect the serosa surface of the uterus and the adnexa. It may be asymptomatic or present as pelvic pain. Endosalpingiosis | risk_factor C17103 risk_factor D C177537 GDC Value Terminology C2996 Dysgerminoma A malignant germ cell tumor characterized by the presence of a monotonous primitive germ cell population. The neoplastic cells form aggregates and have an abundant pale cytoplasm and uniform nuclei. The aggregates of the germ cells are separated by fibrous septa which contain inflammatory cells, mostly T-lymphocytes. It arises primarily in the ovaries, but can occur both primarily and secondarily at other sites, particularly the central nervous system. It responds to chemotherapy and radiotherapy. Its prognosis is related to the tumor stage. 9060/3 | morphology || Dysgerminoma | primary_diagnosis C176985 || C177621 morphology || primary_diagnosis C C177537 GDC Value Terminology C129309 Diffuse Midline Glioma, H3 K27M-Mutant A diffuse midline glioma characterized by the presence of histone H3 K27M mutation. 9385/3 | morphology || Diffuse midline glioma, H3 K27M-mutant | primary_diagnosis C176985 || C177621 morphology || primary_diagnosis C C177537 GDC Value Terminology C151933 Hec1/Nek2 Inhibitor T-1101 Tosylate The tosylate salt form of T-1101, an orally bioavailable inhibitor of highly expressed in cancer 1 (Hec1) and NIMA-related kinase 2 (Nek2), with potential antineoplastic activity. Upon oral administration, T-1101 specifically targets, binds to and inhibits the interaction of Hec1 with Nek2. This prevents Hec1/Nek2-mediated signal transduction pathways, inhibits mitosis, induces apoptosis and tumor cell proliferation. Hec1, overexpressed in some cancers, is located at the centromere during cell mitosis and plays an essential role in the pathway of spindle checkpoint. It is correlated with cancer formation, progression, and survival. Phosphorylation of Hec1 by Nek2 kinase is essential for its mitotic function. Mitosis Inhibitor T 1101 Tosylate | therapeutic_agents C1909 therapeutic_agents C C177537 GDC Value Terminology C37272 Vulvar Intraepithelial Neoplasia, HPV-Independent HPV-negative vulvar squamous intraepithelial proliferation characterized by atypia of the basal and parabasal keratinocytes in an otherwise well-differentiated epithelium. Despite its subtle appearance, it has a high risk of malignant transformation. (WHO 2020) Differentiated-type vulvar intraepithelial neoplasia | primary_diagnosis C177621 primary_diagnosis C C177537 GDC Value Terminology C9459 Borderline Ovarian Brenner Tumor A transitional cell neoplasm of low malignant potential arising from the ovary. It is characterized by the presence of neoplastic transitional cells with atypical features without evidence of stromal invasion. 9000/1 | morphology || Brenner tumor, borderline malignancy | primary_diagnosis || Brenner tumor, proliferating | primary_diagnosis C176985 || C177621 morphology || primary_diagnosis C C177537 GDC Value Terminology C3476 Li-Fraumeni Syndrome An autosomal dominant cancer predisposition syndrome caused by germline mutations of the TP53 gene. It is characterized by the development of malignant neoplasms at various anatomic sites. The malignant neoplasms associated with Li-Fraumeni syndrome include breast carcinoma, choroid plexus carcinoma, adrenal cortex carcinoma, gastric carcinoma, colorectal carcinoma, thyroid gland carcinoma, kidney carcinoma, prostate carcinoma, astrocytic tumors, medulloblastoma, osteosarcoma, soft tissue sarcoma, leukemia, and non-Hodgkin lymphoma. Li-Fraumeni Syndrome | comorbidity || Li-Fraumeni Syndrome | risk_factor C16457 || C17103 comorbidity || risk_factor C C177537 GDC Value Terminology C69313 Cervical Spine The set of vertebrae immediately caudal to the skull. Cervical Spine | biospecimen_anatomic_site || Cervical Spine | treatment_anatomic_site C171435 || C70729 biospecimen_anatomic_site || treatment_anatomic_site C C177537 GDC Value Terminology C33508 Sacrum The triangular bone, made up of 5 fused bones of the spine, located in the lower area of the spine between the fifth lumbar vertebra and the coccyx. Sacrum | biospecimen_anatomic_site || Sacrum | treatment_anatomic_site C171435 || C70729 biospecimen_anatomic_site || treatment_anatomic_site C C177537 GDC Value Terminology C40090 Ovarian Seromucinous Carcinoma A malignant mixed epithelial neoplasm that arises from the ovary and is composed predominantly of serous and endocervical-type mucinous cells. Seromucinous carcinoma | primary_diagnosis C177621 primary_diagnosis C C177537 GDC Value Terminology C158510 BCL2 Inhibitor VOB560 An inhibitor of the anti-apoptotic protein B-cell lymphoma 2 (Bcl-2), with potential pro-apoptotic and antineoplastic activities. Upon intravenous administration, Bcl-2 inhibitor VOB560 binds to and inhibits the activity of Bcl-2, thereby restoring apoptotic processes in tumor cells. Bcl-2 protein is overexpressed in many cancer types and plays an important role in the negative regulation of apoptosis; its expression is associated with increased drug resistance and tumor cell survival. Bcl-2 Inhibitor S65487 | therapeutic_agents C1909 therapeutic_agents C C177537 GDC Value Terminology C2892 Nevoid Basal Cell Carcinoma Syndrome An autosomal dominant genetic syndrome caused by abnormalities in the PTCH and SUFU gene. It is characterized by multiple basal cell carcinomas at a young age, odontogenic keratocysts, and skeletal defects (bifurcated and splayed ribs, fusion of vertebrae, spinal bifida). Patients with this syndrome may also develop medulloblastomas and ovarian fibromas. Gorlin Syndrome | comorbidity || Gorlin Syndrome | risk_factor C16457 || C17103 comorbidity || risk_factor C C177537 GDC Value Terminology C8991 Malignant Mastocytosis A group of malignant mast cell disorders including aggressive systemic mastocytosis, mast cell leukemia, mast cell sarcoma, and systemic mastocytosis with an associated hematological neoplasm. Individuals with advanced systemic mastocytosis have a reduced life expectancy, with median survival measured in months to years. 9741/3 | morphology || Malignant mastocytosis | primary_diagnosis C176985 || C177621 morphology || primary_diagnosis C C177537 GDC Value Terminology C40177 Uterine Corpus Smooth Muscle Tumor of Uncertain Malignant Potential A smooth muscle neoplasm that arises from the uterine corpus and cannot be reliably diagnosed as benign or malignant, because of the presence of ambiguous morphologic findings. 8897/1 | morphology || Smooth muscle tumor of uncertain malignant potential | primary_diagnosis C176985 || C177621 morphology || primary_diagnosis